1. Home
  2. WWR vs ANTX Comparison

WWR vs ANTX Comparison

Compare WWR & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WWR
  • ANTX
  • Stock Information
  • Founded
  • WWR 1977
  • ANTX 2017
  • Country
  • WWR United States
  • ANTX United States
  • Employees
  • WWR N/A
  • ANTX N/A
  • Industry
  • WWR Metal Mining
  • ANTX Biotechnology: Pharmaceutical Preparations
  • Sector
  • WWR Basic Materials
  • ANTX Health Care
  • Exchange
  • WWR Nasdaq
  • ANTX Nasdaq
  • Market Cap
  • WWR 36.9M
  • ANTX 37.6M
  • IPO Year
  • WWR N/A
  • ANTX 2022
  • Fundamental
  • Price
  • WWR $0.89
  • ANTX $1.12
  • Analyst Decision
  • WWR
  • ANTX Hold
  • Analyst Count
  • WWR 0
  • ANTX 5
  • Target Price
  • WWR N/A
  • ANTX $3.50
  • AVG Volume (30 Days)
  • WWR 908.7K
  • ANTX 110.0K
  • Earning Date
  • WWR 03-18-2025
  • ANTX 03-27-2025
  • Dividend Yield
  • WWR N/A
  • ANTX N/A
  • EPS Growth
  • WWR N/A
  • ANTX N/A
  • EPS
  • WWR N/A
  • ANTX N/A
  • Revenue
  • WWR N/A
  • ANTX N/A
  • Revenue This Year
  • WWR N/A
  • ANTX N/A
  • Revenue Next Year
  • WWR N/A
  • ANTX N/A
  • P/E Ratio
  • WWR N/A
  • ANTX N/A
  • Revenue Growth
  • WWR N/A
  • ANTX N/A
  • 52 Week Low
  • WWR $0.40
  • ANTX $0.87
  • 52 Week High
  • WWR $1.32
  • ANTX $21.40
  • Technical
  • Relative Strength Index (RSI)
  • WWR 56.05
  • ANTX 31.57
  • Support Level
  • WWR $0.85
  • ANTX $1.09
  • Resistance Level
  • WWR $1.32
  • ANTX $1.14
  • Average True Range (ATR)
  • WWR 0.11
  • ANTX 0.04
  • MACD
  • WWR -0.00
  • ANTX -0.01
  • Stochastic Oscillator
  • WWR 30.37
  • ANTX 10.00

About WWR Westwater Resources Inc.

Westwater Resources Inc focused on developing battery-grade natural graphite materials. The company is having one project which is the Westwater's coosa project which is currently used for the mining and extraction of graphite.

About ANTX AN2 Therapeutics Inc.

AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease.

Share on Social Networks: